NEW CASTLE, Del., Aug. 13, 2012 (GLOBE NEWSWIRE) -- ScripsAmerica Inc. (OTCBB:SCRC), a leading supplier of prescription, OTC and nutraceutical drugs, today announced the completion of the research and development phase for its RapiMed pain reliever for children. ScripsAmerica's manufacturer will begin production of the RapiMed formulations and anticipates the product line will be available for distribution during the first quarter of 2013.
The Company has utilized a patented technology in the formulation of RapiMed tablets, a fast-acting, solid-dose rapid-melt product that dissolves in a child's mouth in under 30 seconds. The children's pain reliever will come in two doses and in two flavors, grape and bubblegum. The Company strongly believes that RapiMed's popular flavors and great convenience will give the product a competitive advantage in the children's analgesic market.
Bob Schneiderman, CEO of ScripsAmerica, stated, "We are very pleased to complete the R&D phase for RapiMed, a premium-quality children's pain reliever that boasts great flavor and utilizes a delivery technology that provides enhanced convenience. The children's analgesic market has been in turmoil recently due to ongoing recalls of other major branded product lines along with many regulatory failures due to manufacturing from other types of pain relievers in tablet and liquid form. We believe this has created an opening in the market for a superior product like RapiMed."
Director of Marketing and Brand Development for ScripsAmerica, Wade Ambler, added, "We strongly believe that RapiMed will have a competitive advantage in the children's analgesic market due not only to patented material that makes it dissolve more quickly than competing products, but also to other proprietary factors such as flavors, binders, coating agents, package design materials and the manufacturing process. ScripsAmerica is confident that once consumers try our RapiMed children's analgesic tablets, it will be a no-brainer for them to make repeat purchases because they are much easier to administer to small children."
For more information please visit: www.ScripsAmerica.com.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.